IDEAYA Biosciences Newsroom

RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61

Moomoo NewsJan 15 07:33 ET · Ratings

Express News | Cantor Fitzgerald Reiterates Overweight on IDEAYA Biosciencesto Overweight

BenzingaJan 13 09:31 ET

IDEAYA Biosciences Analyst Ratings

BenzingaJan 13 09:30 ET · Ratings

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Tech-Driven Gains Falter at Year-End

MT NewswiresDec 30, 2024 09:02 ET

BTIG Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62

Moomoo NewsDec 30, 2024 06:31 ET · Ratings

IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

MT NewswiresDec 30, 2024 04:34 ET

Reported Sunday, IDEAYA Biosciences Secures Global License For SHR-4849, A Novel Phase 1 DLL3-Targeting ADC For SCLC And NET Tumors

BenzingaDec 30, 2024 02:33 ET

IDEAYA Biosciences: Strategic Acquisition and Promising Clinical Data Drive Buy Recommendation

TipRanksDec 29, 2024 14:05 ET

IDEAYA Biosciences (IDYA): A Down Year Presents a Window of Opportunity for Investors

TipRanksDec 29, 2024 11:18 ET

Express News | Hengrui Pharmaceuticals Says Co Signs Shr-4849 Project License Agreement With IDEAYA Biosciences

ReutersDec 29, 2024 03:49 ET

Jiangsu Hengrui Pharmaceuticals (600276.SH): Signed a licensing agreement for the SHR-4849 project with IDEAYA Biosciences.

On December 29, Gu Longhui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced an agreement with IDEAYA Biosciences, whereby the company granted IDEAYA Biosciences a paid license for the injectable new drug SHR-4849, which has independent intellectual property rights. SHR-4849 is an antibody-drug conjugate (ADC) targeting DLL3 developed by Hengrui with its own intellectual property.

Gelonghui FinanceDec 29, 2024 03:45 ET

Express News | IDEAYA Biosciences Says Its Board Of Directors Granted Non-qualified Stock Options To Purchase An Aggregate Of 31,400 Shares Of Company's Common Stock To A Newly Hired Employee

BenzingaDec 27, 2024 06:06 ET

Express News | IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 27, 2024 06:00 ET

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR NewswireDec 27, 2024 06:00 ET

Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $55

Moomoo NewsDec 23, 2024 08:32 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and IDEAYA Biosciences (IDYA)

TipRanksDec 23, 2024 08:01 ET · Ratings

Companies Like IDEAYA Biosciences (NASDAQ:IDYA) Are In A Position To Invest In Growth

Simply Wall StDec 20, 2024 06:20 ET

IDEAYA Biosciences (IDYA) Receives a Hold From Leerink Partners

TipRanksDec 18, 2024 00:37 ET · Ratings

RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61

Moomoo NewsDec 17, 2024 12:31 ET · Ratings

Express News | Cantor Fitzgerald Reiterates Overweight on IDEAYA Biosciencesto Overweight

BenzingaDec 17, 2024 09:03 ET